



Ribonexus

ICCS, BOSTON, JUNE 5TH, 2023

COMPANY ORIGINS AND OVERVIEW


FOUR SOURCES OF FOUNDATIONAL IP





- Mission: to discover & develop therapeutics targeting mRNA translation with specific focus on chemo resistant cancer
- Developing best in class small molecule inhibitors of mRNA translation
- Preclinical stage company with FIH studies planned for 2024
- Established in 2021 with technology from Pierre Fabre and 3 major French research institutes
- Headquartered in Paris
- €4m seed round supported by AdBio, Credit Mutuel and Pierre Fabre



eIF4A IS A THERAPEUTIC TARGET IN CANCER




- Translation is initiated by the eIF4F complex, consisting of eIF4G, eIF4E and eIF4A protein components
- Oncogenic mRNAs tend to have long and structured 5'UTRs. Structured 5'UTRs interfere with efficient ribosome scanning
- eIF4A is an RNA helicase that unwinds RNA secondary structures in the 5'UTR
- eIF4A1 is upregulated in cancer cells and levels of eIF4A1 protein have been shown to negatively correlate with patient survival
- By selectively modulating eIF4A-dependent translation, it would be possible to reduce translation of mRNAs encoding oncoproteins while maintaining the translation of mRNAs encoding non-oncogenic proteins




Steinmann et al, IJMS, 2023, 24,2055

RBX LEAD SERIES – FLAVAGLINES


DIFFERENTIATED MECHANISM OF ACTION AND DRUG PROPERTIES





A2058 Melanoma
BRAFV600 (BRAFi/MEKi-resistant)



cMYC protein levels in H358




- Library of flavaglines with eIF4Ai activity
- Composition of matter IP estate
- Physico-chemical profile for lead series
- pK data – oral and IV administration potential
- *In vitro* synergy with BRAFi, MEKi, EGFRi, KRASi
- In vivo monotherapy activity
- Expanded knowledge of MoA



MULTIPLE PIPELINE MILESTONES 2022 – 2025

PRIMARY FOCUS ON POORLY MET MEDICAL NEEDS IN ONCOLOGY BUT EMERGING
PROGRESS IN INFLAMMATION



FUTURE CORPORATE MILESTONES



Series A Process Launched: Key Deliverables

- Nomination of oncology clinical candidate (RXBO-1 program)
- RBXO-1 FIH Phase I safety and tolerability data
- Lead candidate from follow on series – differentiated chemophore from program 1
- Preclinical candidate in non-oncology indication

Key Partnering Objectives

- Future licensing partners for RBXO-01
- Collaborative partners for non-oncology (RBXIF-01) program
- Accessing complementary technology and product assets